CTI BIOPHARMA CORP (CTIC)
US12648L6011 - Common Stock
| MRQ (2023-3-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 24.21M | 30.42M | 65.45M | 40.40M | 31.10M | |||
| Marketable Securities | 34.80M | 49.52M | 0.00 | 12.10M | 2.50M | |||
| Receivables | 22.96M | 15.39M | N/A | N/A | 0.00 | |||
| Inventories | 777.00K | 733.00K | N/A | N/A | N/A | |||
| Other Current Assets | 3.71M | 3.34M | 2.93M | 1.90M | 1.90M | |||
| Total Current Assets | 86.45M | 99.40M | 68.38M | 54.30M | 35.60M | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.89M | 2.08M | 3.29M | 2.90M | 4.60M | |||
| Intangibles | 22.70M | 23.23M | N/A | N/A | N/A | |||
| Other Non-Current Assets | 1.23M | 1.23M | 770.00K | 1.00M | 6.10M | |||
| Total Non-Current Assets | 25.82M | 26.53M | 4.05M | 3.90M | 10.70M | |||
| TOTAL ASSETS | 112.27M | 125.92M | 72.43M | 58.20M | 46.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 50.40M | 47.94M | 47.38M | 4.50M | 4.80M | |||
| Accrued Expenses | 14.80M | 30.18M | 13.88M | 9.40M | 13.60M | |||
| Accounts Payable | 2.02M | 2.01M | 3.89M | 1.60M | 0.00 | |||
| Other Current Liabilities | 1.00M | 1.00M | 1.50M | 1.60M | 100.00K | |||
| Total Current Liabilities | 68.23M | 81.13M | 66.65M | 17.00M | 18.50M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 68.37M | 61.13M | 0.00 | 0.00 | 4.50M | |||
| Other Non-Current Liabilities | 1.02M | 1.23M | 2.02M | 1.20M | 5.40M | |||
| Total Non-Current Liabilities | 69.39M | 62.37M | 2.02M | 1.20M | 4.10M | |||
| TOTAL LIABILITIES | 137.62M | 143.50M | 68.67M | 18.20M | 22.60M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -2.53B | -2.52B | -2.43B | -2.33B | -2.26B | |||
| Additional Paid In Capital | 2.51B | 2.50B | 2.43B | 2.37B | 2.30B | |||
| Minority Interest | N/A | N/A | N/A | 0.00 | -5.80M | |||
| Common Shares | 132.00K | 131.00K | 100.00K | 100.00K | 100.00K | |||
| Other Shareholders' Equity | -11.00K | -35.00K | 0.00 | 0.00 | -12.00M | |||
| Shares Outstanding | 131.88M | 130.75M | 99.76M | 75.90M | 58.00M | |||
| Tangible Book Value per Share | -0.36 | -0.31 | 0.04 | 0.53 | 0.41 | |||
| Total Shareholders' Equity | -25.35M | -17.58M | 3.77M | 40.00M | 23.70M | |||
| TOTAL LIABILITIES AND EQUITY | 112.27M | 125.92M | 72.43M | 58.20M | 46.30M | |||
| Statistics | ||||||||
| Debt/Equity | -2.70 | -3.48 | N/A | N/A | 0.19 | |||
| Current Ratio | 1.27 | 1.23 | 1.03 | 3.19 | 1.92 | |||
| Return On Assets (ROA) | -61.67% | -73.85% | -135.17% | -90.12% | -86.44% | |||
| Return On Equity (ROE) | N/A | N/A | -2599.10% | -131.13% | -168.86% | |||
All data in USD